Is Atherosclerosis Regression a Realistic Goal of Statin Therapy and What Does That Mean?

Statin Drugs (MB Clearfield, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Statin Drugs


Atherosclerosis is a complex disease associated with aberrant lipoprotein metabolism and leukocyte infiltration into arterial tissue that leads to cardiovascular diseases. Statins have emerged as among the most effective means of reducing the risk of cardiovascular disease in both primary and secondary prevention settings. Statins are the only pharmacological agents that have been consistently shown to have antiatherosclerotic effects. Statins slow atherosclerosis progression and can even induce atherosclerosis regression. Technological advances in imaging modalities to assess atherosclerosis have made possible direct visualization of atherosclerotic plaques and estimation of plaque burden and permit the evaluation of the impact of medical therapies on the natural history of plaque progression. However, owing to several limiting factors as discussed in this review, presently atherosclerotic plaque progression cannot be used as a therapeutic goal for reduction of the risk of cardiovascular disease. In this review we discuss the evidence for the use of imaging modalities in the detection of atherosclerotic plaque regression, the effects of statins on the atherosclerotic process, and the clinical relevance of atherosclerosis regression.


Statin Atherosclerosis regression Vascular imaging 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature. 2008;451:904–13.PubMedCrossRefGoogle Scholar
  2. 2.
    Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet. 1997;349:1436–42.PubMedCrossRefGoogle Scholar
  3. 3.
    Beaglehole R, Bonita R. Global public health: a scorecard. Lancet. 2008;372:1988–96.PubMedCrossRefGoogle Scholar
  4. 4.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.Google Scholar
  6. 6.
    Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615–22.PubMedCrossRefGoogle Scholar
  7. 7.
    Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22.CrossRefGoogle Scholar
  9. 9.
    Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Sipahi I, Tuzcu EM. Candidate mechanisms for regression of coronary atherosclerosis with high-dose statins: insight from intravascular ultrasonography trials. Am J Cardiovasc Drugs. 2008;8(6):365–71.PubMedCrossRefGoogle Scholar
  11. 11.
    Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–74.PubMedCrossRefGoogle Scholar
  12. 12.
    Vogel RA. Cholesterol lowering and endothelial function. Am J Med. 1999;107:479–87.PubMedCrossRefGoogle Scholar
  13. 13.
    Zaman AG, Helft G, Worthley SG, Badimon JJ. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis. 2000;149:251–66.PubMedCrossRefGoogle Scholar
  14. 14.
    Libby P. Changing concepts of atherogenesis. J Intern Med. 2000;247:349–58.PubMedCrossRefGoogle Scholar
  15. 15.
    Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.PubMedCrossRefGoogle Scholar
  16. 16.
    Glagov S, Weisneberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.PubMedCrossRefGoogle Scholar
  18. 18.
    Klein LW. Atherosclerosis regression, vascular remodeling, and plaque stabilization. J Am Coll Cardiol. 2007;49:271–3.PubMedCrossRefGoogle Scholar
  19. 19.•
    Shanmugam N, Román-Rego A, Ong P, Kaski JC. Atherosclerotic plaque regression: fact or fiction? Cardiovasc Drugs Ther. 2010;24(4):311–7. This article discusses the evaluation of plaque regression and its effect on survival.PubMedCrossRefGoogle Scholar
  20. 20.
    Williams KJ, Feig JE, Fisher EA. Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat Clin Pract Cardiovasc Med. 2008;5:91–102.PubMedCrossRefGoogle Scholar
  21. 21.
    Ortego M, Bustos C, Hernández-Presa MA, Tuñón J, Díaz C, Hernández G, et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999;147:253–61.PubMedCrossRefGoogle Scholar
  22. 22.••
    Tardif JC, Lesage F, Harel F, Romeo P, Pressacco J. Imaging biomarkers in atherosclerosis trials. Circ Cardiovasc Imaging. 2011;4:319–33. This review discusses various imaging modalities for detection of atherosclerosis, their application, strengths, and limitations.PubMedCrossRefGoogle Scholar
  23. 23.
    Chambless LE, Zhong MM, Arnett D, Folsom AR, Riley WA, Heiss G. Variability in B-mode ultrasound measurements in the atherosclerosis risk communities (ARIC) study. Ultrasound Med Biol. 1996;22(5):545–54.PubMedCrossRefGoogle Scholar
  24. 24.
    Geroulakos G, O’Gorman DJ, Kalodiki E, Sheridan DJ, Nicolaides AN. The carotid intima-media thickness as a marker of the presence of severe symptomatic coronary artery disease. Eur Heart J. 1994;15:781–5.PubMedGoogle Scholar
  25. 25.
    Burke GL, Evans GW, Riley WA, Sharrett AR, Howard G, Barnes RW, et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Stroke. 1995;26:386–91.PubMedCrossRefGoogle Scholar
  26. 26.
    Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction. Circulation. 1997;96:1432–7.PubMedCrossRefGoogle Scholar
  27. 27.
    O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340:14–22.PubMedCrossRefGoogle Scholar
  28. 28.
    Touboul PJ, Elbaz A, Koller C, for the GÉNIC Investigators, et al. Common carotid artery intima–media thickness and brain infarction: The Étude du Profile Génétique de l’Infarctus Cérébral (GÉNIC) case–control study. Circulation. 2000;102(3):313–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness consensus (2004–2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007;23(8):75–80.PubMedCrossRefGoogle Scholar
  30. 30.
    Stein JH, Korcarz CE, Hurst RT, et al. American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21(10):93–112.PubMedGoogle Scholar
  31. 31.
    Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis. Stroke. 2004;35(12):2902–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Bedi US, Singh M, Singh PP, Bhuriya R, Bahekar A, Molnar J, et al. Effects of statins on progression of carotid atherosclerosis as measured by carotid intimal–medial thickness: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2010;15(3):268–73.PubMedCrossRefGoogle Scholar
  33. 33.
    Mannami T, Konishi M, Baba S, Nishi N, Terao A. Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular high risk factors in the general population of a Japanese city: the Suita study. Stroke. 1997;28(3):518–25.PubMedCrossRefGoogle Scholar
  34. 34.
    Crouse JR, Raichlen JS, Riley WA, for the METEOR study group, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. The METEOR Trial. JAMA. 2007;297(6):1344–53.PubMedCrossRefGoogle Scholar
  35. 35.
    Groot E, Jukema JW, van Swijndregt ADM, et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol. 1998;31(4):1561–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized, controlled clinical trial. Ann Intern Med. 1996;24(6):548–56.Google Scholar
  37. 37.
    Furberg CD, Adams Jr HP, Applegate WB, for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90(4):1679–87.PubMedCrossRefGoogle Scholar
  38. 38.
    Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJP, Stalanhoef AFH. Effects of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP). Lancet. 2001;357(8):577–81.PubMedCrossRefGoogle Scholar
  39. 39.
    Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. Arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness (ARBITER). Circulation. 2002;106(3):2055–60.PubMedCrossRefGoogle Scholar
  40. 40.
    MacMahon S, Sharpe N, Gamble G, et al. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. Circulation. 1998;97(8):1784–90.PubMedCrossRefGoogle Scholar
  41. 41.
    Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the β-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation. 2001;103(1):1721–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Yu CM, Zhang Q, Lam L, et al. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal–medial thickness in patients with coronary heart disease. Heart. 2007;93(7):933–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intima–media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med. 1996;101:627–34.PubMedCrossRefGoogle Scholar
  44. 44.
    Nissen SE, Yock P. Intravascular ultrasound: novel pathophysiological insights and current clinical applications. Circulation. 2001;103:604–16.PubMedCrossRefGoogle Scholar
  45. 45.
    Nissen SE. Application of intravascular ultrasound to characterize coronary artery disease and assess the progression or regression of atherosclerosis. Am J Cardiol. 2002;89:24B–31B.PubMedCrossRefGoogle Scholar
  46. 46.
    Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556–65.PubMedCrossRefGoogle Scholar
  47. 47.
    Jang IK, Bouma BE, Kang DH, Park SJ, Park SW, Seung KB, et al. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound. J Am Coll Cardiol. 2002;39:604–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Aoki J, Rodríguez-Granillo GA, Serruys PW. Emergent strategies in interventional cardiology. Rev Esp Cardiol. 2005;58:962–73.PubMedCrossRefGoogle Scholar
  49. 49.
    Nissen SE, Tuzcu EM, Schoebnhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071–80.PubMedCrossRefGoogle Scholar
  50. 50.
    Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292–300.PubMedCrossRefGoogle Scholar
  51. 51.
    Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation. 2004;110:1061–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217–25.PubMedCrossRefGoogle Scholar
  53. 53.
    Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499–508.PubMedCrossRefGoogle Scholar
  54. 54.••
    Santos RD, Nasir K. Insights into atherosclerosis from invasive and non-invasive imaging studies: Should we treat subclinical atherosclerosis? Atherosclerosis. 2009;205(2):349–56. This article discusses the treatment of subclinical atherosclerosis.PubMedCrossRefGoogle Scholar
  55. 55.
    Bedi U, Singh M, Singh P, Molnar J, Khosla S, Arora R. Effects of statins on progression of coronary artery disease as measured by intravascular ultrasound. J Clin Hypertens (Greenwich). 2011;13(7):492–6.CrossRefGoogle Scholar
  56. 56.
    Jensen LO, Thayssen P, Pedersen KE, et al. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation. 2004;110:265–70.PubMedCrossRefGoogle Scholar
  57. 57.
    Schartl M, Bocksch W, Koschyk DH, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation. 2001;104:387–92.PubMedCrossRefGoogle Scholar
  58. 58.
    Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29–38.PubMedCrossRefGoogle Scholar
  59. 59.
    Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827–32.PubMedCrossRefGoogle Scholar
  60. 60.
    Callister TQ, Cooil B, Raya SP, Lippolis NJ, Russo DJ, Raggi P. Coronary artery disease: improved reproducibility of calcium scoring with and electron-beam CT volumetric method. Radiology. 1998;208:807–14.PubMedGoogle Scholar
  61. 61.
    Detrano R, Tang W, Kang X, Mahaisavariya P, McCrae M, Garner D, et al. Accurate coronary calcium phosphate mass measurements from electron beam computed tomograms. Am J Card Imaging. 1995;3:167–73.Google Scholar
  62. 62.
    Hoff JA, Daviglus ML, Chomka EV, Krainik AJ, Sevrukow A, Kondos GT. Conventional coronary artery disease risk factors and coronary artery calcium detected by electron beam tomography in 30,908 healthy individuals. Ann Epidemiol. 2003;13:163–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Secci A, Wong N, Tang W, Wang S, Doherty T, Detrano R. Electron beam computed tomographic coronary calcium as a predictor of coronary events. Circulation. 1997;96:1122–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med. 2004;164:1285–92.PubMedCrossRefGoogle Scholar
  65. 65.
    Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology. 2003;228:826–33.PubMedCrossRefGoogle Scholar
  66. 66.
    Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291:210–5.PubMedCrossRefGoogle Scholar
  67. 67.•
    Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O’Leary D, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308(8):788–95. This article compares the risk markers for improvement of risk stratification in intermediate-risk individuals.PubMedCrossRefGoogle Scholar
  68. 68.
    Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med. 1998;339:1972–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Schmermund A, Erbel R. Unstable coronary plaque and its relation to coronary calcium. Circulation. 2001;104:1682–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Budoff MJ, Raggi P. Coronary artery disease progression assessed by electron-beam computed tomography. Am J Cardiol. 2001;88:46E–50E.PubMedCrossRefGoogle Scholar
  71. 71.
    Achenbach S, Ropers D, Pohle K, Leber A, Thilo C, Knez A, et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation. 2002;106:1077–82.PubMedCrossRefGoogle Scholar
  72. 72.
    Schmermund A, Achenbach S, Budde T, Buziashvili Y, Förster A, Friedrich G, et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation. 2006;113:427–37.PubMedCrossRefGoogle Scholar
  73. 73.
    Schoenhagen P, Tuzcu EM, Stillman AE, Moliterno DJ, Halliburton SS, Kuzmiak SA, et al. Non-invasive assessment of plaque morphology and remodeling in mildly stenotic coronary segments: comparison of 16-slice computed tomography and intravascular ultrasound. Coron Artery Dis. 2003;14:459–62.PubMedCrossRefGoogle Scholar
  74. 74.
    Achenbach S, Ropers D, Hoffmann U, MacNeill B, Baum U, Pohle K, et al. Assessment of coronary remodeling in stenotic and nonstenotic coronary atherosclerotic lesions by multidetector spiral computed tomography. J Am Coll Cardiol. 2004;43:842–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Leber AW, Knez A, Becker A, Becker C, von Ziegler F, Nikolaou K, et al. Accuracy of multidetector spiral computed tomography in identifying and differentiating the composition of coronary atherosclerotic plaques: a comparative study with intracoronary ultrasound. J Am Coll Cardiol. 2004;43:1241–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Achenbach S, Moselewski F, Ropers D, Ferencik M, Hoffmann U, MacNeill B, et al. Improved detection of calcified and noncalcified coronary atherosclerotic plaque by contrast-enhanced, submillimeter multidetector spiral computed tomography: a segment-based comparison with intravascular ultrasound. Circulation. 2004;109:14–7.PubMedCrossRefGoogle Scholar
  77. 77.
    Pundziute G, Schuijf JD, Jukema JW, Boersma E, de Roos A, van der Wall EE, et al. Prognostic value of multislice computed tomography coronary angiography in patients with known or suspected coronary artery disease. J Am Coll Cardiol. 2007;49:62–70.PubMedCrossRefGoogle Scholar
  78. 78.
    Min JK, Shaw LJ, Devereux RB, Okin PM, Weinsaft JW, Russo DJ, et al. Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. J Am Coll Cardiol. 2007;50:1161–70.PubMedCrossRefGoogle Scholar
  79. 79.
    Corti R. Noninvasive imaging of atherosclerotic vessels by MRI for clinical assessment of the effectiveness of therapy. Pharmacol Ther. 2006;110:57–70.PubMedCrossRefGoogle Scholar
  80. 80.••
    Tang TY, Howarth SP, Miller SR, Graves MJ, Patterson AJ, U-King-Im JM, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultra small super-paramagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol. 2009;53:2039–50. This article demonstrated that aggressive lipid-lowering therapy with atorvastatin over a 3-month period is associated with significant reduction in carotid plaque inflammation evaluated with ultrasmall superparamagnetic iron oxide enhanced magnetic resonance imaging.PubMedCrossRefGoogle Scholar
  81. 81.
    Underhill HR, Yuan C, Zhao XQ, Kraiss LW, Parker DL, Saam T, et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J. 2008;155:584.e1–8.PubMedCrossRefGoogle Scholar
  82. 82.
    Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001;103:926–33.PubMedCrossRefGoogle Scholar
  83. 83.
    Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years’ follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation. 2002;106:2884–7.PubMedCrossRefGoogle Scholar
  84. 84.
    Yonemura A, Momiyama Y, Fayad ZA, Ayaori M, Ohmori R, Higashi K, et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol. 2005;45:733–42.PubMedCrossRefGoogle Scholar
  85. 85.
    Lima JA, Desai MY, Steen H, Warren WP, Gautam S, Lai S. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation. 2004;110:2336–41.PubMedCrossRefGoogle Scholar
  86. 86.
    Kawasaki M, Sano K, Okubo M, et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. J Am Coll Cardiol. 2005;45:1946–53.PubMedCrossRefGoogle Scholar
  87. 87.
    Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.PubMedCrossRefGoogle Scholar
  88. 88.
    Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349:847–58.PubMedCrossRefGoogle Scholar
  89. 89.
    Berry C, L’Allier PL, Grégoire J, Lespérance J, Levesque S, Ibrahim R, et al. Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression. Circulation. 2007;115:1851–7.PubMedCrossRefGoogle Scholar
  90. 90.
    Brown BG. A direct comparison of intravascular ultrasound and quantitative coronary arteriography: implications for measures of atherosclerosis as clinical surrogates. Circulation. 2007;115:1824–6.PubMedCrossRefGoogle Scholar
  91. 91.
    Schoenhagen P, Tuzcu EM, Apperson-Hansen C, Wang C, Wolski K, Lin S, et al. Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation. 2006;113:2826–34.PubMedCrossRefGoogle Scholar
  92. 92.
    Ballantyne CM, Raichlen JS, Nicholls SJ, Erbel R, Tardif JC, Brener SJ, et al. The ASTEROID Investigators. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography. a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008;117:2458–66.PubMedCrossRefGoogle Scholar
  93. 93.
    Brener SJ, Ivanc TB, Poliszczuk R, Chen M, Tuzcu EM, Hu T, et al. Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine Versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials. Am Heart J. 2006;152:1059–63.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Department of CardiologyChicago Medical SchoolNorth ChicagoUSA
  2. 2.Department of CardiologyOchsner ClinicNew OrleansUSA

Personalised recommendations